Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia?

Human Psychopharmacology

Volumn 13, Issue 4, 1998, Pages 231-237

  Joffe, Grigori ^a   Nyberg, Peter ^b   Gross, Andres ^a   Appelberg, Björn ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Mjolbolsta Hospital   (Finland)

Author keywords

Blood phagocytes; Clozapine; Reactive oxygen species; Schizophrenia; Treatment resistance

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; REACTIVE OXYGEN METABOLITE;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MALE; MONOCYTE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031858007     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199806)13:4<231::AID-HUP976>3.0.CO;2-J     Document Type: Conference Paper

References (35)

1. APA (1987). DSM-III-R. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, rev. American Psychiatric Association, Washington.
2. Banati, R., Gehrmann, J., Schubert, P. and Kreutzberg, G. (1993). Cytotoxity of microglia. Glia, 7, 111-118.
3. Boukhris, W., Kouassi, E. and Revillard, J. (1988). Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro. Immunopharmacology and Immunotoxicology, 10, 501-512.
4. Cadet, J. and Kahler, L. (1994). Free radical mechanisms in schizophrenia and tardive dyskinesia. Neuroscience and Biobehavioral Reviews, 18, 457-467.
5. Chang, J., Piperata, S., Skowronek, M. and Lewis, A. J. (1983). Effects of thiazinamium chloride, promethazine and chlorpromazine on thromboxane B2 synthesis, phagocytosis and respiratory burst by rat alveolar macrophages. Biochemical Pharmacology, 32, 2671-2677.
6. De Chatelet, L., Long, G. and Shirley, P. (1982). Mechanisms of luminol-dependent chemiluminescence of human neutrophils. Journal of Immunology, 129, 1589-1593.
7. DeLisi, L. (1997). Schizophrenia, genetics, autoimmunity: contradictions and explanations. In Immunological Alterations in Psychiatric Diseases, Henneberg, A. and Kaschka, W. (eds), Advances in Biology and Psychiatry, Vol. 18, Karger, Bazel, pp. 78-84.
8. Denicoff, K., Rubinow, D., Papa, M., Simpson, C., Lotze, M., Chang, A., Rosenstein, D. and Rosenberg, S. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine, 107, 293-300.
9. Fischer, V., Haar, J., Greiner, L., Lloyd, R. and Mason, R. (1991). Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. Molecular Pharmacology, 40, 846-853.
10. Fisher, M. (1988). Monocyte and polymorphonuclear leukocyte toxic oxigen metabolite production in multiple sclerosis. Inflammation, 12, 123.
11. Ganguli, R. and Rabin, B. S. (1989). Increased serum interleukin-2 receptor concentration in schizophrenic and brain damaged persons. Archives of General Psychiatry, 46, 292.
12. Ganguli, R., Brar, J., Chengpappa, K., DeLeo, M., Yang, Z., Shurin, G. and Rabin, B. (1995). Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Archives of General Psychiatry, 52, 668-672.
13. Hickey, W. (1991). Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathology, 1, 97-105.
14. Jann, M., Grimsley, S., Gray, E. and Chang, W. (1993). Pharmacokinetiks and pharmacodynamics of clozapine. Clinical Pharmacokinetics, 24, 161-176.
15. Jeding, I., Evans, P., Akanmu, D., Dexter, D., Spencer, J., Aruoma, O., Jenner, P. and Halliwell, B. (1995). Characterization of the potential antioxidant and prooxidant actions of some neuroleptic drugs. Biochemical Pharmacology, 49, 359-365.
16. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. and the Clozaril Collaborative Study Group (1988). Clozapine for treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 789-796.
17. Kay, S., Fiszbein, A. and Opler, L. (1987). The Positive and Negative syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
18. Ling, E. and Wong, W. (1993). The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia, 7, 9-18.
19. Liu, Z. and Uetrecht, J. (1995). Clozapine is oxidated by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. Journal of Pharmacology and Experimental Therapeutics, 275, 1476-1483.
20. Maes, M., Meltzer, H. and Bosmans, E. (1994). Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica, 89, 346-351.
21. Mahadik, S. and Scheffer, R. (1996). Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrienes, EFAs, 55, 45-54.
22. McAdams, C. and Leonard, B. (1995). Neutrophil and monocyte phagocytosis in depressed patients. Progress in Neuro-Psychopharmacology, Biology Psychiatry, 17, 971-984.
23. McAllister, C., van Kammen, D., Rehn, T., Miller, A., Gurklis, J., Kelley, M., Yao, J. and Peters, J. (1995). Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. American Journal of Psychiatry, 152, 1291-1297.
24. McPhillips, M. and Barnes, T. (1997). Negative symptoms. Current Opinions in Psychiatry, 10, 30-35.
25. Montgomery, S. and Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
26. Müller, N., Empl, M., Putz, A., Schwarz, M. and Ackenheil, M. (1997). Immunological effects of treatment in schizophrenia. In Immunological Alterations in Psychiatric Diseases, Henneberg, A. and Kaschka, W. (eds), Advances in Biology and Psychiatry, Vol. 18, Karger, Bazel, pp. 78-84.
27. O'Neill, B. and Leonard, B. (1990). Abnormal Zymosan-induced neutrophil chemiluminescence as a marker of depression. Journal of Affective Disorders, 19, 265-272.
28. Owens, D. (1996). Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs, 51, 895-930.
29. Pisciotta, A., Konings, S., Ciesemier, L., Cronkite, C. and Lieberman, J. (1992). Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. Journal of Laboratory Clinical Medicine, 119, 254-266.
30. Pollmacher, T., Hinze-Selch, D. and Mullington, J. (1996). Effects of clozapine on plasma cylokine and soluble cytokine receptor levels. Journal of Clinical Psychopharmacology, 16, 403-409.
31. Potkin, S., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Yi, Richmond, G., Carreon, D., Sitamggan, K., Gerber, B., Telford, J., Plon, L., Plon, H., Park, L., Chang, Y. J., Oldroyd, J. and Cooper, T. (1994). Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry, 55 (Suppl. B), 133-136.
32. Rapaport, M., McAllister, C., Pickar, D., Nelson, D. and Paul, S. (1989). Elevated levels of soluble interleukin-2 receptors in schizophrenia. Archives of General Psychiatry, 46, 291-292.
33. Ruutu, T. (1972). Effect of phenotiazines and related compounds on phagocytosis and bacterial killing by human neutrophil leukocytes. Annals of Medical and Experimental Biology Fenniae, 50, 24-36.
34. Smith, R. (1991). The immune system is a key factor in the etiology of psychosocial disease. Medical Hypotheses, 34, 49-57.
35. Thery, C., Chamak, B. and Mallat, M. (1993). Neurotoxity of brain macrophages. Clinical Neuropathology, 12, 288-290.